![Karen Reeves](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karen Reeves
Corporate Officer/Principal at LIGAND PHARMACEUTICALS INCORPORATED
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David R. Elmaleh | M | 76 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 13 years |
Matthew Korenberg | M | 49 | 9 years | |
Todd Davis | M | 63 | 17 years | |
John Kozarich | M | 74 | 21 years | |
Jason Haas | M | 56 | 2 years | |
Martine Zimmermann | M | 55 | 1 years | |
Nancy Gray | M | 64 | 7 years | |
Keith D. Greenfield | M | - |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 10 years |
Andrew Reardon | M | 49 | 2 years | |
Octavio Espinoza | M | 53 | 2 years | |
Jason Aryeh | M | 55 | 18 years | |
Stephen Sabba | M | 64 | 16 years | |
John LaMattina | M | 74 | 13 years | |
Noah Gottdiener | M | 67 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 years |
Peter S. Conti | M | 67 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
Gillian Sandler | F | - |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 6 years |
Ronald G. Tompkins | M | - |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
Audrey Warfield-Graham | F | - | 30 years | |
Richard B. Baxter | M | - | - | |
Thierry Porté | M | 67 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 years |
David Adams Taft | M | 67 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
John Robert Camber Porter | M | 71 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | - |
George D. Behrakis | M | - |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Francis Tirelli | M | - | - | |
Marc M. P. de Garidel | M | 66 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 years |
Jay Mohr | M | - |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 years |
Philip Ashton-Rickardt | M | 60 |
AZTherapies, Inc.
![]() AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 27 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karen Reeves
- Personal Network